Edition:
United States

Allergan plc (AGN)

AGN on New York Consolidated

237.33USD
24 Mar 2017
Change (% chg)

$2.04 (+0.87%)
Prev Close
$235.29
Open
$235.35
Day's High
$238.35
Day's Low
$234.86
Volume
2,688,552
Avg. Vol
4,195,071
52-wk High
$281.28
52-wk Low
$184.50

AGN

Chart for AGN

About

Allergan plc is a specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of brand name pharmaceutical products, medical aesthetics, biosimilar and over-the-counter pharmaceutical products. The Company operates through three segments: US Specialized Therapeutics, US... (more)

Overall

Beta: 1.12
Market Cap(Mil.): $79,558.88
Shares Outstanding(Mil.): 335.22
Dividend: 0.70
Yield (%): 1.18

Financials

  AGN Industry Sector
P/E (TTM): -- 28.94 29.72
EPS (TTM): -3.12 -- --
ROI: -0.75 13.46 13.00
ROE: -1.71 14.38 14.15

BRIEF-Allergan Plc says CEO Brenton Saunders's 2016 total compensation $4.1 mln - SEC Filing

* Allergan Plc- CEO Brenton L. Saunders's 2016 total compensation $4.1 million - SEC Filing

Mar 24 2017

BRIEF-Allergan reports availability of restasis multidose

* Allergan announces availability of restasis multidose™ (cyclosporine ophthalmic emulsion) 0.05 pct -- the first fda-approved preservative free prescription eye drop available in a multidose bottle

Mar 22 2017

BRIEF-Juvéderm Vollure XC approved by FDA for correction of facial wrinkles and folds

* Juvéderm Vollure™ XC approved by U.S. FDA for correction of facial wrinkles and folds in adults over the age of 21

Mar 20 2017

Allergan signs deal with Editas for gene-editing-based eye treatments

Allergan plc said on Tuesday it would get exclusive access and the option to license up to five of Editas Medicine Inc's experimental gene-editing-based eye treatments under a research and development deal between the two companies.

Mar 14 2017

Allergan signs deal with Editas for gene-editing-based eye treatments

Allergan plc said on Tuesday it would get exclusive access and the option to license up to five of Editas Medicine Inc's experimental gene-editing-based eye treatments under a research and development deal between the two companies.

Mar 14 2017

UPDATE 1-Allergan signs deal with Editas for gene-editing-based eye treatments

March 14 Allergan plc said on Tuesday it would get exclusive access and the option to license up to five of Editas Medicine Inc's experimental gene-editing-based eye treatments under a research and development deal between the two companies.

Mar 14 2017

Allergan signs deal with Editas for gene-editing-based eye treatments

March 14 Allergan plc said on Tuesday it would get exclusive access and the option to license up to five of Editas Medicine Inc's experimental gene-editing-based eye treatments under a research and development deal between the two companies.

Mar 14 2017

BRIEF-Allergan and Editas Medicine enter into strategic research and development alliance

* Allergan and Editas Medicine enter into strategic research and development alliance to discover and develop Crispr Genome editing medicines for eye diseases

Mar 14 2017

BRIEF-Cisco appoints Brenton Saunders, CEO Of Allergan Plc, to board of directors

* Cisco appoints brenton l. Saunders, chairman, president and ceo of allergan plc, to board of directors Source text for Eikon: Further company coverage:

Mar 13 2017

BRIEF-Supernus announces settlement with Actavis on Trokendi XR patent litigation

* Supernus announces settlement with Actavis on Trokendi XR patent litigation

Mar 07 2017

More From Around the Web

Earnings vs. Estimates